Johnson & Johnson’s autoimmune drug Stelara (ustekinumab) is encountering biosimilar competition from seven approved products with deep price discounts. Unlike the Humira biosimilar market, Stelara biosimilars mostly lack dual pricing strategies, opting instead for aggressive low pricing. Interchangeability remains a non-issue as most biosimilars hold this designation. As additional biosimilars near approval, market adoption and pricing dynamics will determine competitive positioning in a multibillion-dollar immunology arena.